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INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) can offer a cure for patients with hematologic
malignancies. Although methods are constantly improving,
relapsed disease remains a major limitation to long-term
patient survival. Different strategies have been explored to
address this problem. Increased cytotoxic conditioning regi-
mens have been evaluated but have not been successful in
lowering relapse rates, mainly because of increased toxicity
[1,2]. A second allogeneic transplantation for recurrent dis-
ease has cured only a small number of patients and is also
associated with extensive morbidity and mortality [3-6]. It
has become evident that patients who develop graft-versus-
host disease (GVHD) run a lower risk of recurrent disease
than patients without GVHD. This so-called graft-versus-
leukemia (GVL) effect was first described in humans by
Weiden et al. in 1979 [7] and has been shown to be crucial
for long-term remissions, particularly in patients with
advanced leukemias [8-12]. Both GVHD and GVL are
thought to be mediated by alloreactive donor leukocytes
(T cells and natural killer [NK] cells) recognizing host his-
tocompatibility antigens. This supposition has led to the
testing of donor buffy coat infusions to augment GVL activ-
ity of bone marrow allografts [13] and subsequently to the
use of donor lymphocyte infusions (DLIs) as a treatment for
leukemic relapse after HSCT [14-17].
The best response to DLI is seen in patients with
relapsed chronic myelogenous leukemia (CML), in whom
complete remissions (CRs) have been reported in 60% to
80% of these treated patients [16,18-20]. For patients with
acute leukemia, the results are less encouraging, with an ini-
tial response rate between 10% and 20% [16,18,19]. The
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ABSTRACT
Between 1991 and 1999, 44 leukemic patients received donor lymphocyte infusions (DLIs) at our center (22 patients
with chronic myelogenous leukemia [CML]; 10 with acute myelogenous leukemia; 11 with acute lymphatic leukemia;
and 1 with myelodysplastic syndrome). Seventeen patients received graft-versus-host disease (GVHD) prophylaxis
with methotrexate (MTX) at the time of DLI. In CML patients, 15 of 22 (68%) re-entered complete remission after
DLI. At 3 years post-DLI, patients with cytogenetic (n = 10) or molecular (n = 3) relapse had a current leukemia-free
survival (cLFS) rate of 85% compared with 0% for patients with hematologic relapse (P < .001). Among 15 CML
patients who initially responded to DLI, 4 patients relapsed within the first 2 years. Four of 16 patients (25%) with
acute leukemia had an initial response with complete remission after DLI. Two of them subsequently relapsed within
1 year. Patients with acute leukemia who relapsed within 1 year of hematopoietic stem cell transplantation (n = 9) had
0% cLFS at 18 months; patients with later relapse had 29% cLFS (P = .015). The overall probability of cLFS at
3 years for CML patients was 46%. For other diseases, cLFS was 13% at 18 months after DLI. Patients who devel-
oped chronic GVHD secondary to DLI showed a 3-year cLFS of 51% compared with 18% for patients without
chronic GVHD (P = .022). This study emphasizes the importance of early disease stage and presence of chronic
GVHD for effective DLI.
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success of DLI in inducing remission is highly correlated to
the incidence of acute and chronic GVHD [18], but the
mediators of the GVL effect have been difficult to isolate
from those causing GVHD. Severe acute GVHD (grades II
to IV) subsequent to DLI is common, with incidences vary-
ing between 40% and 55% [16,18,20]. Other adverse effects,
such as pancytopenia, have been reported in almost 20% of
patients [18]. These effects contribute to the toxicity of DLI,
resulting in a treatment-related mortality of up to 20% [20].
A thorough understanding of the effects and the kinetics
of DLI treatment is essential to optimize treatment proto-
cols. Because many of the previous follow-ups on DLI
treatment were based on data from multiple centers with
varying, nonstandardized treatment strategies, we wanted to
evaluate the outcome at our own center. Therefore, we per-
formed a retrospective analysis of all DLI-treated patients
with leukemia or myelodysplastic syndrome (MDS).
MATERIALS AND METHODS
Patients and Donors
This study includes 44 patients (22 with CML, 10 with
acute myelogenous leukemia [AML], 11 with acute lymphatic
leukemia [ALL], and 1 with MDS) who received transplants
between 1986 and 1999. They all received DLI treatment
between 1991 and 1999. Thirty patients were given conven-
tional bulk doses of donor lymphocytes containing variable
numbers of CD3+ T cells (bulk dose regimen [BDR]). The
remaining patients (n = 14) received escalating doses of lym-
phocytes containing predeﬁned numbers of CD3+ cells (esca-
lating dose regimen [EDR]). For the majority of patients 
(n = 38), DLI was given as treatment for recurrent disease, but
some patients in the EDR group (n = 6) received DLI prophy-
lactically, to prevent relapse. The patients treated with a pro-
phylactic regimen were included in the study for the evaluation
of side effects of DLI. Main patient and donor characteristics
are depicted in Table 1. Details regarding conditioning proto-
cols and immunosuppressive regimens have been described in
detail [21-23]. The study was granted permission by the local
ethics committee. Oral consent was obtained from the patients.
Definition of Relapse
Patients who relapse after HSCT do so in a sequential
manner, with relapse recognizable first at the molecular
level, then at the cytogenetic level, and ﬁnally with hemato-
logic evidence of leukemia. For CML patients, a molecular
relapse was deﬁned as evidence of recurrent disease only by
reverse transcription–polymerase chain reaction (RT-PCR)
for bcr/abl messenger RNA (mRNA). All patients (CML and
non-CML) who had reappearance of a disease-speciﬁc chro-
mosome abnormality by fluorescence in situ hybridization
or conventional cytogenetics but no morphological signs of
disease were defined as cytogenetic relapses. Relapse with
detectable disease in blood or bone marrow by morphologi-
cal analyses was deﬁned as hematologic.
Definition of Response
Hematologic remission was achieved if a patient with
previous hematologic relapse attained normal blood counts
and normalized bone marrow morphology. A patient was
considered to have achieved a cytogenetic remission if no dis-
ease-speciﬁc chromosome abnormality was detectable in the
marrow upon cytogenetic analysis. Patients with CML were
considered to have achieved a molecular remission when
bcr/abl transcripts no longer could be detected by RT-PCR.
Donor Leukocyte Infusions
Donor cells were collected by leukapheresis on one or
more occasions, depending on the cell yield. No donor was
stimulated with growth factors before leukapheresis. BDR
patients received cells fresh. For EDR patients, buffy coat
Table 1. Pretreatment Characteristics of Patients and Donors*
Overall BDR† EDR‡
n 44 30 14
Patient age, y 30 (3-58) 33 (4-58) 25 (3-53)
Donor age, y 35 (2-61) 35 (2-60) 29 (20-61)
Patient sex, M/F 28/16 20/10 8/6
Donor sex, M/F 30/14 19/11 11/3
Diagnosis
AML 10 5 5
ALL 11 7 4
CR1§ 7 — —
>CR1 14 — —
CML 22 17 5
CP1 20 — —
>CP1 2 — —
Cytogenetic relapse 10 8 2
Molecular relapse 3 0 3
Hematologic relapse 9 9 0
MDS 1 1 0
HLA-matched donor
Sibling 24 15 9
Parent 1 0 1
Unrelated 14 13 1
Related donor, 1 antigen 1 1 0 
mismatched
Unrelated donor, 1 antigen 4 1 3
mismatched
Conditioning regimen
CY + TBI 42 28 14
BU + CY 2 2 0
T cell–depleted HSCT 6 — —
GVHD after HSCT 13 — —
Grade I 26 — —
Grade II 4 — —
Grade III 1 — —
Cell dose¶ — 2.7 (0.1-32) 0.2 (0.02-3.1)
*Data are n or median (range). BDR indicates bulk dose regimen;
EDR, escalating dose regimen; AML, acute myelogenous leukemia;
ALL, acute lymphatic leukemia; CR1, ﬁrst complete remission; CML,
chronic myelogenous leukemia; CP, chronic phase; MDS, myelodys-
plastic syndrome; CY, cyclophosphamide; TBI, total body irradiation;
BU, busulfan; HSCT, hematopoietic stem cell transplantation;
GVHD, graft-versus-host disease.
†Patients who received single or multiple infusions of bulk donor
buffy coat cells.
‡Patients who received escalating doses of donor buffy coat cells,
based on the number of CD3+ cells. This group also comprised
6 patients receiving DLI prophylactically.
§CR1 at time of HSCT; >CR1 at time of HSCT.
HLA-A, -B and -DR identical.
¶Nucleated cells  108/kg recipient.
31-38.00-048-Carlens  2/15/01  2:49 PM  Page 32
Role of Disease Stage in DLI
corresponding to 105 to 106 CD3+ cells/kg recipient body
weight constituted the initial cell dose. The remaining cells
obtained from the leukapheresis were cryopreserved with
autologous plasma and dimethyl sulfoxide in 1-log incre-
ments, with respect to the content of CD3+ cells. Based on
an estimated cell loss of 30% to 50% in the preservation
procedure itself, the cell doses were doubled before freez-
ing. A subsequent DLI dose was usually increased by 0.5
to 1 log.
Patients with CML in hematologic relapse were in some
cases treated with hydroxyurea, but this drug was discontin-
ued before DLI. Only occasional patients with acute leukemia
were given pre-DLI chemotherapy. Different immunosup-
pressive and immunostimulatory regimens were used in con-
junction with DLI, especially in the earlier years of the time
studied. All patients had cyclosporine withdrawn when the
relapse diagnosis was confirmed. Nine patients received
GVHD prophylaxis with methotrexate (MTX) alone,
10 mg/m2 intravenously, on days 1, 3, and 7 after DLI. Eight
patients received MTX, as described above, in combination
with various interleukin (IL)-2 regimens. In most cases, IL-2
was given in an initial infusion of 9 million units intra-
venously for 24 hours, followed by 2 million units subcuta-
neously/day for 4 weeks [24]. In a few cases, IL-2 was instead
given in a dose of 6 million U/m2 per day subcutaneously for
3 consecutive days [25]. Six patients were treated with IL-2
alone, whereas the remaining 21 patients received no
immunomodulatory treatment in conjunction with DLI.
Patients were monitored with cytogenetic analyses on
an individual basis after DLI, depending on the diagnosis.
At each outpatient visit, full blood counts were taken to fol-
low hematologic relapses. Patients with CML treated for
molecular or cytogenetic relapse were checked with PCR
for bcr/abl transcripts before each DLI and every 4 to 6
weeks after DLI.
Diagnosis, Grading, and Treatment of GVHD
Acute and chronic GVHD were diagnosed on the basis
of clinical symptoms or veriﬁed by biopsies (skin, liver, gas-
trointestinal tract, or oral mucosa). Acute GVHD was
graded on a scale from 0 to IV according to published crite-
ria [26]. Grade I to II acute GVHD was treated with
2 mg/kg per day of prednisolone for 1 week, and the dose
was then tapered [22,27]. In patients with progressive symp-
toms, prednisolone treatment was prolonged. For more
severe cases, methylprednisolone (0.125 to 0.5 g/d), antithy-
mocyte globulin, psoralen and ultraviolet A light (PUVA),
or additional MTX was also given [27,28]. Chronic GVHD
was graded as limited or extensive. The overall severity was
deﬁned as mild, moderate, or severe. Mild disease included
sicca and minor symptoms affecting the skin and/or liver
with a Karnofsky score of 90%. Moderate disease involved
symptoms affecting 1 or several organs that could be con-
trolled by immunosuppression but required prolonged or
continuous therapy. The Karnofsky score in these patients
ranged from 70% to 80%. Severe disease was defined as
restricted functions, including such symptoms as malabsorp-
tion, sclerosis of the skin, severe bronchiolitis, etc., with
Karnofsky scores below 70% [29,30]. Chronic GVHD was
treated with cyclosporine and steroids. If a poor initial
response was seen, some patients also received PUVA.
Statistical Analysis
Results were analyzed in April 2000, allowing for a
median follow-up time of 38 months (range, 3-173 months).
Time to relapse was analyzed from the time of DLI by the
life-table method with the log-rank test (Mantel-Haenszel),
taking censored data into account [31]. The definition of
current leukemia-free survival (cLFS) implies living patients
who are in remission following DLI treatment for a
leukemic relapse. However, because the median time to a
remission usually varies between 1 and 3 months [18]
depending on the diagnosis, the patients in the cLFS analy-
ses responding to DLI treatment had, to a varying degree,
not yet re-entered remission during this initial time period.
The patients receiving lymphocytes prophylactically (n = 6)
were, by deﬁnition, not in relapse at the time of DLI and
were therefore excluded from the survival analyses. For
comparison of discrete data, the Fisher exact test was
employed. Differences were considered significant when
probability values were ≤.05. Otherwise, they were consid-
ered nonsigniﬁcant (NS).
RESULTS
Response to DLI and Duration of Remission
Patients with CML had a cLFS of 46% at 3 years after
DLI, compared with 13% at 18 months for patients with
other diagnoses (P = .018) (Figure 1). However, as depicted
in Figure 1, the maximum follow-up time for the latter
patients was <2 years. Of 22 treated CML patients, 15
(68%) re-entered CR after DLI. In this group, 4 of
5 patients treated by EDR responded (80%), compared
with 11 of 17 patients (65%) treated by BDR (P = .54). At
3 years post-DLI, patients with cytogenetic (n = 10) or
molecular (n = 3) relapse had a cLFS of 85%; patients with
accelerated phase or hematologic relapse had a cLFS of 0%
(P < .001) (Figure 2). Among 15 patients with CML ini-
tially responding to DLI, 4 patients subsequently relapsed
within 2 years. A relapse occurred in 1 patient almost
9 years after DLI treatment. The median time from DLI to
relapse of CML was 13 months (range, 1-104 months). Of
16 patients with acute leukemia, 4 (25%) responded and
went into CR after DLI. Of these, 2 patients subsequently
relapsed within 1 year after DLI. Patients with acute
leukemia relapsing within 1 year of HSCT (n = 9) had 0%
cLFS at 18 months, compared with 29% in patients with
later relapses (P = .015) (Figure 3). No differences were
seen between outcomes for patients with early (first CR)
and later (beyond first remission) disease at HSCT.
Furthermore, no significant differences in cLFS could be
detected when comparing pat ients  with di f ferent
MTX/IL-2 regimens, but the individual groups were small.
Among CML patients initially not responding to DLI, 4 of
5 patients with hematologic relapse and 0 of 2 patients with
cytogenetic relapse had received MTX. Among CML
patients subsequently relapsing after having achieved a
remission (n = 5), 3 of 4 patients with an initial hemato-
logic relapse had been given MTX after DLI, but not the
1 patient with cytogenetic relapse. Among the CML
patients who responded and stayed in remission, 5 of 10
were given MTX after DLI.
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GVHD, Thrombocytopenia/Neutropenia, and 
Causes of Death
Acute GVHD occurred in 12 of 43 evaluable patients
(28%). Chronic GVHD occurred in 21 of 44 patients
(48%). Table 2 shows the absolute incidences and the overall
severity for acute and chronic GVHD for all patients and
for patients treated by BDR or EDR. Although the inci-
dence of GVHD grades II to IV was somewhat lower in the
EDR group (8%) than in the BDR group (27%), this was
not statistically significant (NS) (P = .20). Patients who
developed chronic GVHD after DLI showed a 3-year cLFS
of 51% compared with 18% for patients without chronic
GVHD (P = .022) (Figure 4). Among the 15 patients who
developed chronic GVHD, 10 patients had CML and
5 patients had non-CML disease. A separate analysis of
patients with CML showed a 3-year cLFS of 69% in
patients developing chronic GVHD (n = 10) compared with
27% in patients without chronic GVHD (n = 12) (P = .058).
Development of GVHD after the initial transplantation
(P = .18) and donor type (related or unrelated [P = .59]) had
no significant impact on the development of chronic
GVHD after DLI. Furthermore, the development of acute
Figure 1. Probability of current leukemia-free survival (cLFS) in chronic myelogenous leukemia (CML) patients compared with patients with other
diagnoses (acute leukemia [AL] or myelodysplastic syndrome [MDS]). An event is either death or relapse. The initial drop in cLFS represents all
patients not re-entering remission after donor lymphocyte infusion. The cLFS was measured from the time of donor lymphocyte infusion.
Figure 2. Probability of current leukemia-free survival (cLFS) in patients with chronic myelogenous leukemia in cytogenetic or molecular relapse
compared with patients with hematologic relapse. There were 10 patients in cytogenetic remission and 3 patients in molecular remission. The cLFS
was measured from the time of donor lymphocyte infusion. An event is either death or a relapse. The initial drop in cLFS represents all patients not
re-entering remission after donor lymphocyte infusion.
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GVHD after DLI had no predictive value for the outcome.
Patients with acute GVHD had a 3-year cLFS of 24% com-
pared with 34% for patients without acute GVHD. Four of
17 patients receiving MTX after DLI developed acute
GVHD grades II to IV, compared with 5 of 26 patients not
given MTX (NS). The administration of IL-2 after DLI did
not increase GVHD incidence compared with patients not
receiving IL-2. None of the 6 patients receiving IL-2 treat-
ment alone developed acute GVHD grades II to IV.
Thrombocytopenia, defined as platelet counts <30 
109/L, occurred in 5 patients (11%); among those, 4 patients
also developed neutropenia, with neutrophil counts <0.5 
109/L. Of the 4 patients with neutropenia, 3 had acute
leukemia and 1 had CML in accelerated phase. Among these,
only 1 patient with acute leukemia achieved a lasting remis-
sion. Recurrent disease was the predominant cause of death
(87%), followed by infection (9%) (Table 2). GVHD was a
contributing cause of death in 6 patients (26%), comprising
4 patients with acute and 2 patients with chronic disease.
DISCUSSION
Recurrent disease remains one of the major causes of
treatment failure after HSCT [32-34]. Regimens that have
previously been used for the prevention and treatment of
leukemic relapse include increased cytotoxic conditioning
regimens [1,2], additional chemotherapy in combination
with granulocyte colony-stimulating factor [35], and a sec-
ond transplantation [3-6]. Unfortunately, results have been
discouraging, with few long-term surviving patients. More
recently, DLI has been shown to induce potent GVL effects
and reinduce complete remissions. Initial response rates vary
between 60% and 80% for patients with CML and between
10% and 20% for patients with acute leukemia [16,18-20].
Because treatment strategies and methods vary between
centers and many of the previously published studies are
based on data collected from a number of different centers,
we evaluated the outcome after DLI therapy at our own
institution. Because the response to DLI is clearly different
in CML patients compared with other diagnoses, the results
Figure 3. Probability of current leukemia-free survival (cLFS) in patients with diseases other than chronic myelogenous leukemia (early versus late
relapse). Patients with acute leukemia (n = 15) or myelodysplastic syndrome (n = 1) relapsing within 1 year of hematopoietic stem cell transplanta-
tion had 0% cLFS at 18 months, compared with 29% in patients with later relapses. An event is either death or relapse. The initial drop in cLFS
represents all patients not re-entering remission after donor lymphocyte infusion (DLI).
Table 2. Absolute Incidence of GVHD and Causes of Death After DLI*
All patients BDR† EDR‡
n 44 30 14
Acute GVHD
Grade 0 31 (72) 20 (67) 11 (85)
Grade I 3 (7) 2 (7) 1 (8)
Grade II 5 (12) 5 (17) 0
Grade III 3 (7) 2 (7) 1 (8)
Grade IV 1 (2) 1 (3) 0
No data§ 1 0 1
Chronic GVHD
None 23 (52) 17 (57) 6 (43)
Mild 10 (23) 5 (17) 5 (36)
Moderate 8 (18) 8 (27) 0
Severe 3 (7) 0 3 (21)
GVHD at death
Acute 4 (17) 3 1
Chronic 2 (9) 2 0
Cause of death
Infection 2 (9) 1 1
Relapse 20 (87) 19 1
Other/unknown 1 (4) 1 0
*Data are n or n (%). GVHD indicates graft-versus-host disease;
DLI, donor lymphocyte infusion; BDR, bulk dose regimen; EDR, esca-
lating dose regimen.
†Patients recieving single or multiple infusions of bulk donor buffy
coat cells.
‡Patients recieving escalating doses of donor buffy coat cells, based
on the number of CD3+ cells. This group also comprised 6 patients
recieving DLI prophylactically.
§Lost to follow-up.
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are often stratiﬁed by diagnosis. Among our 22 patients with
CML, the initial response rate was 68%. However, during
the first 2 years, 4 patients relapsed, resulting in a 3-year
cLFS of 46%. One late relapse occurred almost 9 years after
DLI. Both the initial response rate and the proportion of
patients relapsing were somewhat higher than those
reported by Porter et al. [20] in a recent long-term follow-
up. There was a significant difference in cLFS between
CML patients in cytogenetic or molecular relapse and
patients with a hematologic relapse. In fact, none of the
patients with hematologic relapse achieved a durable remis-
sion (lasting more than a year) after receiving DLI. We
believe that the poor response rate in this group of patients
was not caused by unfavorable disease features, because only
2 patients were in accelerated-phase CML and the remain-
ing 7 patients were in chronic-phase CML.
One may speculate whether the various MTX regimens
used at our center have contributed to nonresponsiveness
after DLI, considering the absolute incidences of acute and
chronic GVHD were as low as 28% and 48%, respectively.
These rates of occurrence are lower than 41% [16] and 60%
[18] for acute and chronic GVHD, respectively, previously
reported in 2 large multicenter studies. Overall, we were not
able to detect a higher incidence of relapse among patients
receiving MTX compared with that of other patients. How-
ever, among CML patients with hematologic relapse, 4 of
5 patients not responding to DLI had received MTX after
DLI. Also, among CML patients with hematologic relapse—
initially re-entering CR but subsequently relapsing again—
3 of 4 patients had received MTX after DLI. However, the
various groups make it difficult to draw a firm conclusion
regarding the possible role of MTX in incidences of GVHD
and relapse. Our current belief is that immunosuppression
should be avoided at the time of DLI because the GVL
effect is most likely hampered by it.
For patients treated by EDR, 4 of 5 (80%) re-entered
remission after DLI, compared with 11 of 17 patients (65%)
treated by BDR (NS). The group of patients treated by
EDR received a substantially lower total cell dose than that
received by patients treated by BDR (Table 1). On the other
hand, patients treated by EDR were all in cytogenetic or
molecular relapse, not hematologic relapse. It has been sug-
gested that patients with larger tumor cell burdens, as in the
case of a hematologic relapse, require larger DLI cell doses
than do patients in cytogenetic or molecular relapses
[15,17]. Our data, although not statistically signiﬁcant, tend
to support this hypothesis. As expected, the incidence of
acute GHVD grades II to IV tended to be lower (8%) in the
EDR group than in the BDR group (27%). This discrep-
ancy may be due to the lower number of cells given in the
EDR group, but as Dazzi et al. [17] recently showed, the
difference could also be due to the fact that cells given by
EDR are administered over a longer period. No difference
in the incidence of chronic GVHD could be seen between
the 2 dose regimens in our patients (57% and 43% in the
EDR and BDR groups, respectively [NS]).
When evaluating all 44 patients for cLFS, a signiﬁcant
antileukemic effect was seen in patients with chronic GVHD,
compared with all other patients. The antileukemic effects of
chronic GVHD after HSCT are well known [10,34]. GVHD
secondary to DLI has also been shown to be closely associ-
ated with the response rate [16,18]. Our current study con-
ﬁrms this by showing a 3-year cLFS of 51% for patients with
chronic GVHD compared with 18% for all other patients
(P = .022). CML patients have been shown to be more prone
to chronic GVHD [36] and generally have a higher response
rate to DLI, which may contribute to the large discrepancy
seen here. On the other hand, a separate analysis of patients
with CML showed a 3-year cLFS of 69% in patients develop-
ing chronic GVHD compared with 27% in patients without
chronic GVHD. However, due to a low number of patients in
each group, this difference was of only borderline statistical
signiﬁcance (P = .058). We saw no signiﬁcant differences in
the outcomes for patients with or without acute GVHD.
Figure 4. Probability of current leukemia-free survival in patients developing chronic graft-versus-host disease (cGVHD) compared with all other
patients (no cGVHD). DLI indicates donor lymphocyte infusion.
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For patients with diseases other than CML, the out-
come after DLI is less promising, with a cLFS at 18 months
of 13% in the current study. None of 9 patients diagnosed
with a recurrent disease within 1 year after HSCT achieved
a remission after DLI. For patients relapsing beyond 1 year
after HSCT, the response rate was 29% at 18 months after
DLI (P = .015).
These results clearly indicate the need for close moni-
toring, early diagnosis of recurrent disease, and aggres-
sive treatment regimens for these patients. Innovative
approaches that could limit the toxicity from DLI and
potentially allow a more intense cell therapy are needed.
Augmenting the GVL effect by IL-2 administration has, in
some cases, been successful [24,25,37]. Modification of
donor T cells by suicide genes that can abrogate GVHD
[38,39] and the selective depletion of CD8+ T cells from
the donor product [40] are strategies currently being
explored. The use of EDR will most likely be able to
reduce the toxicity of DLI [17]. An alternative approach
would be to expand and enrich cells with more direct anti-
tumor effects. It has been shown that CML patients relaps-
ing after HSCT have low numbers of NK cells compared
with patients still in remission [41]. Because NK cells are
also thought to be among the main effectors of the GVL
effect [42], one may further explore the adoptive transfer of
NK cells [43,44].
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